Bioluminescent tool captures neural activity without external lasers
December 12, 2025
A decade ago, a group of scientists had the literally brilliant idea to use bioluminescent light to visualize brain activity.
A decade ago, a group of scientists had the literally brilliant idea to use bioluminescent light to visualize brain activity.
P&F USA, Inc., the U.S. subsidiary of heart valve manufacturer P&F Products and Features GmbH, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the TRICAV II Pivotal Trial.
Study is first to show how tanning beds mutate skin cells far beyond the reach of ordinary sunlight
The Bendit17 steerable microcatheter aims to advance navigational control through complex anatomies in vascular procedures.
The Spring is the only FDA-approved FIT in a range of lengths and diameters, allowing for patient personalisation
A European research project led by VTT has developed machine vision mimicking the cooperation of the eye and nervous system, implemented as edge-computing circuits.
PLANO, Texas, Dec. 11, 2025 /PRNewswire/ — Vesalio, a leader in thrombectomy solutions, today announced FDA 510(k) clearance and the upcoming U.S. commercial launch of enVast™, the first and only clot retriever specifically cleared for mechanical thrombectomy in the cardiac circulation. enVast introduces a proven, innovative approach to clot capture and removal, redefining coronary thrombectomy for patients with large thrombus burden (LTB).
An interdisciplinary research team from Dresden University of Technology (TUD), Rostock University Medical Center (UMR) and Dresden University Hospital has developed an innovative, implantable and fully absorbable sensor film.
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even years after treatment.
Heart muscle cells grown from patient stem cells—known as human induced pluripotent stem cell–derived cardiomyocytes, or hiPSC-CMs—are a promising way to repair hearts damaged by heart attacks and heart failure.